Evidence map›Paper›PMID 39199786›Full record

ArticleBioengineering (Basel, Switzerland)2024

Perlecan: An Islet Basement Membrane Protein with Protective Anti-Inflammatory Characteristics.

Daniel Brandhorst, Heide Brandhorst, Samuel Acreman, Paul R V Johnson

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Daniel BrandhorstIslet Transplant Research Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.
Heide BrandhorstIslet Transplant Research Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.
Samuel AcremanIslet Transplant Research Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.ORCID 0000-0001-5117-4447
Paul R V JohnsonIslet Transplant Research Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.ORCID 0000-0003-3142-137X

Funding

Diabetes Research and Wellness Foundation (DRWF) n.a.European Union's Horizon 2020 645991Juvenile Diabetes Research Foundation 31-2008-617Oxford NIHR Biomedical Research Centre Theme n.a.
6 · The paper itself

Abstract

Throughout the isolation process, human islets are subjected to destruction of the islet basement membrane (BM) and reduced oxygen supply. Reconstruction of the BM represents an option to improve islet function and survival post-transplant and may particularly be relevant for islet encapsulation devices and scaffolds. In the present study, we assessed whether Perlecan, used alone or combined with the BM proteins (BMPs) Collagen-IV and Laminin-521, has the ability to protect isolated human islets from hypoxia-induced damage. Islets isolated from the pancreas of seven different organ donors were cultured for 4-5 days at 2% oxygen in plain CMRL (sham-treated controls) or in CMRL supplemented with BMPs used either alone or in combination. Postculture, islets were characterized regarding survival, in vitro function and production of chemokines and reactive oxygen species (ROS). Individually added BMPs significantly doubled islet survival and increased in vitro function. Combining BMPs did not provide a synergistic effect. Among the tested BMPs, Perlecan demonstrated the significantly strongest inhibitory effect on chemokine and ROS production when compared with sham-treatment (

Indexed as

collagen type IVextracellular matrix proteinshuman islet isolationhypoxiainflammationislet basement membranelaminin-521perlecan

Identifiers

PMID39199786
PMCPMC11351669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.